• 대한한방내과학회지
• /
• 제38권2호
• /
• pp.164-171
• /
• 2017

Objectives: The purpose of this case report is to describe the efficacy of Saenggan-tang-gagam treatment in a patient with immune-tolerant chronic hepatitis B who converted to the immune active phase during hospitalization for Intracerebral hemorrhage. Methods: A 61-year-old male patient with chronic hepatitis B was hospitalized from July 21, 2016 to October 24, 2016. On September 5, the patient showed fatigue and dyspepsia, and his urine was dark. These symptoms were accompanied by a dramatic elevation of aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) levels. Saenggan-tang-gagam was administered three times a day until the patient was discharged from the hospital. Results: After the Saenggan-tang-gagam treatment, AST and ALP levels decreased significantly, below the upper limit level. In addition, the levels of ALT and GG were significantly decreased. In addition, the fatigue, dyspepsia, and dark urine induced by hepatitis improved after the Saenggan-tang-gagam treatment. Conclusion: This case report suggests that traditional Korean medicine has a beneficial effect on the immune active phase of chronic hepatitis B.

• Journal of Yeungnam Medical Science
• /
• 제33권2호
• /
• pp.150-154
• /
• 2016

Hepatitis C virus (HCV) infection is present in a high proportion of patients with kidney transplantation. Compared with uninfected kidney transplant recipients, HCV infected kidney recipient have higher prevalence of liver disease and worse allograft survival after transplantation. Interferon monotherapy before transplantation is standard therapy for HCV-infected kidney transplant candidates. If HCV infection is discovered after transplantation, interferon monotherapy is considered due to the limited critical situation. However, in this patient, who was a kidney recipient, HCV infection was treated after kidney transplantation with peginterferon-${\alpha}$ and rivabirin. As a result, the patient achieved sustained virologic response.

• 한국임상약학회지
• /
• 제22권1호
• /
• pp.81-86
• /
• 2012

This study was aimed to examine the prescribing patterns of antivirals in outpatients with chronic hepatitis B (CHB), using National Health Insurance adjudicated claims data (total 1,426,065 claims) dated March 19, 2008 submitted from nationwide healthcare providers to Health Insurance Review and Assessment Service. From the data, there were 2,965 claims with CHB diagnosis (ICD-10 code B18.0 and B18.1), and 44.2% (1,311 claims) of the CHB related claims included antivirals such as lamivudine, clevudine, adefovir and entecavir. Lamivudine, adefovir, clevudine and entecavir shared 54.9%, 19.9%, 13.2% and 11.9%, respectively, among antiviral prescriptions. Adefovir and entecavir 1mg presumed as the 2nd line therapy for HBV resistant cases were shared 23.3% of overall antiviral prescriptions. There were statistically significant difference in prescription patterns according to age and institution type: Lamivudine usage was higher in younger (< 20 years old) and older age group (> 70 years old) than the others (p = 0.016), and adefovir and entecavir, which were relatively newer antivirals, had higher prescription rates in higher level of institutions such as tertiary hospitals than the others (p < 0.001). This study would be of help to make an appropriate drug therapy plan for patients with CHB.

• 한국임상약학회지
• /
• 제26권3호
• /
• pp.220-229
• /
• 2016

Background: The treatment goal for patients with chronic hepatitis B infection is to prevent progression of the disease to cirrhosis and hepatocellular carcinoma. Current therapies include standard and pegylated interferon-alfa and nucleoside/nucleotide analogues: lamivudine, adefovir, entecavir, telbivudine, clevudine, and tenofovir. This study aims to analyze changes in the prescribing patterns of chronic hepatitis B (CHB) medications in South Korea between 2013 and 2014. Methods: A cross-sectional study was conducted using National Patients Sample data compiled by the Health Insurance Review and Assessment Service from 2013 and 2014. Patients with CHB were identified with Korean Standard Classification of Diseases code-6 (B18.0 and B18.1) and those who were maintaining active prescriptions with CHB medications covering the index date (December $1^{st}$, each year) were included. The utilization of antiviral therapy was investigated during 2013 and 2014. Results: A total of 4,204 and 4,552 patients in 2013 and 2014 respectively, were included in the analysis. The proportion of male patients was two of third and the patients 41-60 years old accounted for 60% of all analyzed patients. The most utilized drug was entecavir (55.1% in 2013 and 44.8% in 2014) and the second most utilized drug was tenofovir in both years (18.8% in 2013 and 29.0% in 2014). The percentage of combination therapy was 13.6% and 13.1% in 2013 and 2014, respectively. The proportion of tenofovir prescriptions was increased in 2014 compared with 2013. Conclusion: With the development of new drugs and the changes in clinical practice guidelines, the prescription pattern of the antiviral agents for patients with CHB has changed. The rate of utilization of tenofovir has increased.

• 대한한방내과학회지
• /
• 제19권1호
• /
• pp.22-38
• /
• 1998

This study was to investigate the hepatoprotective and anticirrhotic effects of Ganyeumilhobang(GIE) on the acute and chronic liver injury induced by various agents. Chronic liver injury induced by dimethylnitrosamine(DMN) ; a new experimental model for cirrhosis and the intraperitoneal injection of dimethylnitrosamine in the rat. Acute liver njury induced by carbon tetrachloride$(CCl_4)$ and D-galactosamine ; a experimental model for acute liver injury, the administration of $CCl_4$ and the intraperitoneal injection of D-galactosamine in the rat. The development of fibrosis and acute liver injury by the three prescriptions were examined by the chemical analysis of AST, ALT, prothrombin time and hydroxyproline. The results obtained were as follows. 1. The increasing level of hydroxyproline volume induced by DMN in mice was decreased by the oral administration of GIB. 2. The degree of histological fibrosis and hepatic inflammatory cell infiltration induced by $CCl_4$ decreased by the oral administration of GIB. 3. The increase of senun AST and ALT of mice with acute liver damage induced by $CCl_4$ and D-galactosamine was inhibited by the administration of GIB. 4. The prolongation of prothrombin time(seconds) of mice acute liver damage induced by $CCl_4$ was shortened by the oral administration of GIB. 5. The liver of mice was hepatectomized partial1y after the oral administration of GIB. The mitotic index(% of nuclei), weight of liver, contents of protein, RNA and DNA synthesis of the liver tissue were increased by the oral administration of GIB.

• 대한한방내과학회지
• /
• 제27권4호
• /
• pp.1014-1026
• /
• 2006

Liver cirrhosis is a liverdisease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Liver cirrhosis is regarded as a serious health problem with high prevalence in the world as well as in Korea. Liver cirrhosis is an irreversible disease. However, in cases of liver cirrhosis induced by chronic hepatitis B, we should treat the chronic hepatitis B, because it frequently progresses to cirrhosis and hepatoma. We observedimprovements of symptoms and laboratory tests with herb medicine Injinchunggan-tang (茵蔯淸肝湯) in five cases ofliver cirrhosis and chronic hepatitis B. The serum aminotransferase was preserved within normal value levels for a long time, 3 years to 7 years. However, further study is necessary to determine the effect of herb medicine on liver cirrhosis and chronic hepatitis B.

• 동의생리병리학회지
• /
• 제18권1호
• /
• pp.306-309
• /
• 2004

Liver cirrhosis is caused by virus, alcohol, toxins, drugs and chronic hepatitis. Clinical symptoms of liver cirrhosis are severe fatigue, nausea, fever, dyspepsia, anorexia, RUQ pain, jaundice, ascites. We applied oriental medicines to patient who had chronic hepatitis and liver cirrhosis. Sodalgeonbitang-gamibang has been used to treat hepatitis and liver cirrhosis because of its beneficial effects. The patient symptoms began to improve after about one month of treatment. After medication we could find remarkable effect on clinical symptoms and blood test. So we hope that this clinical study is helpful in treat a patient with hepatic disease.

• 대한한방내과학회지
• /
• 제37권2호
• /
• pp.374-380
• /
• 2016

Objective: Although the incidence of chronic hepatitis B has decreased around the world due to widespread national preventative control measures, mortality from the same condition can increase if the condition leads to liver cancer or liver cirrhosis. In most cases, herbal medicine does not show any statistically significant effects related to liver damage, but preconceptions do exist that herbal medicine can be toxic and cause such liver damage. To investigate this situation, this study therefore investigated a patient with hepatitis B who had combined traditional Korean medicine therapy and the use of analgesic drugs during a hospitalization period.Method: A patient with hepatitis B was given combined traditional Korean medicine therapy and the use of analgesic drugs during a hospitalization period.Results: Within 26 days, the patient was free from liver damage during the hospitalization period. She was followed up with a liver function test and was discharged after her condition improved; she also reported decreased back pain.

• Biomolecules & Therapeutics
• /
• 제9권2호
• /
• pp.131-139
• /
• 2001

Lamivudine, an oral nucleoside analogue, effectively inhibits hepatitis B virus replication and reduces hepatic necroinflammation in patients with chronic hepatitis B. Although lamivudine has shown a promise in patients with chronic hepatitis B, a long-term data on Korean patients with hepatitis B are lacking. The purpose of this study is to evaluate the effects and safety of 52-week lamivudine therapy in Korean patients with chronic hepatitis B, A total of twenty-nine patients (27 male and 2 female) who had received 100 mg of oral lamivudine daily for 52 weeks were evaluated, retrospectively. The mean age of 29 patients in the study group was 37.7 $\pm$ 8.9 years (range 19-54). Pretreatment HBV PCR and HBsAg were positive in all 29 patients, and HBeAg were positive in 25 patients (86%). The serum HBV DNA of 28 patients (97%) significantly fell to undetectable levels (<5 pg/ml) within 12 weeks of therapy and it remained undetectable in 24 patients (83%) by the end of 52-week therapy (p<0.001). Mean serum ALT levels of 29 patients declined to the normal range within 12 weeks and remained within the normal range during the evaluative period (p<0.05). The proportions of patients with HBeAg seroconversion (loss of HBeAg, development of antibody to HBeAg, and undetectable HBV DNA) were 42% after 52-week therapy. The differences of response to lamivudine therapy in HBeAg- positive and HBeAg-negative patients were negligible (p>0.05). Furthermore, the study showed that pretreatment serum HBV DNA and ALT levels have no effect to the efficacy of lamivudine therapy (p>0.05). Further comparison of lamivudine's efficacy showed that lamivudine is just as efficacious in patients with cirrhosis as without cirrhosis (p>0.05). In conclusion, lamivudine is an effective and safe therapy for the treatment of chronic hepatitis B in Korean patients.

• 생명과학회지
• /
• 제15권6호
• /
• pp.948-954
• /
• 2005

민간에서 만성간염, 수종, 옹종, 습진, 류마치스성 관절통, 소변분리, 말라리아, 황달을 치료하는데 사용하며, 해열 진통제로 약용하고 있는 배풍등을 metanol (SLM)로 먼저 추출하고 이를 hexane (SLMH), ethylether (SLMEE), ethylacetate(SLMEh), butanol (SLMB) 및 수층 (SLMA) 등 다섯가지의 각 용매별로 분획하여 배풍등의 항균 및 항발암 효과를 연구하였다. 먼저 paper disc method를 이용하여 배풍등의 항균효과를 알아보았다. P. mirabilis, S. aureus, S. marcescens 및 B. substilis의 4가지 사용균주에 배풍등의 각 분획물을 처리한 결과, 모든 균주에서 SLMEA층에서 가장 높은 항균 활성 효과를 나타내었고, 그 다음으로는 SLMEE에서 항균 활성 효과를 나타내었다. 배풍등의 암세포 증식억제 효과(cytotoxicity)를 MTT assay로 실험한 결과, 4종의 암세포주 HeLa, MCF-7, HT-29 및 HepG2 모두 배풍등의 ethylether 분획층인 SLMEE총에서 가장 높은 암세포 증식억제 효과를 보였으며, 암예방 QR유도 활성을 HepG2 세포주를 이용하여 실험한 결과에서도, 다른 분획층에 비해 비극성 용매층인 SLMEE층에서 유의적으로 QR유도 활성을 증가시키는 것으로 나타났다. 이상의 실험 결과를 미루어 볼 때, 극성과 비극성을 둘 다 가지는 SLMEA층에서의 항균활성 물질과 비극성 용매층인 SLMEE 층에서의 암 예방 물질의 단계적인 분리 동정을 통한 생리활성 물질의 개발이 기대되어진다.